Metabolism Unit, Department of Endocrinology, Metabolism and Diabetes; Molecular Nutrition Unit, Center for Innovative Medicine; KI/AZ Integrated CardioMetabolic Center (ICMC), Department of Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, S-141 86 Stockholm, Sweden.
Metabolism Unit, Department of Endocrinology, Metabolism and Diabetes; Molecular Nutrition Unit, Center for Innovative Medicine; KI/AZ Integrated CardioMetabolic Center (ICMC), Department of Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, S-141 86 Stockholm, Sweden.
Trends Mol Med. 2017 Feb;23(2):97-99. doi: 10.1016/j.molmed.2016.12.006. Epub 2017 Jan 10.
Effectively treating metabolic syndrome and its progression to type 2 diabetes, steatohepatitis and cardiovascular disease remain a major clinical challenge. The use of a novel engineered molecule that combines thyroid hormone and glucagon to target liver and adipose tissue might provide a new 'magic bullet' with exciting future prospects.
有效治疗代谢综合征及其向 2 型糖尿病、脂肪性肝炎和心血管疾病的进展仍然是一个主要的临床挑战。一种新型工程分子的使用，该分子结合了甲状腺激素和胰高血糖素，以靶向肝脏和脂肪组织，可能提供一种具有令人兴奋的未来前景的新“灵丹妙药”。
